poisar

Stocks · News reference

Equita Maintains Buy Rating on Ascopiave Amid Regulatory Tax Changes

Fiscal.ai

Following a portfolio adjustment in response to proposed Italian IRAP tax increases for utility companies, Equita has maintained its 'buy' recommendation for Ascopiave.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading